BIAL invests €30 million in strengthening production capacity

Strengthening the production capacity and autonomy in the supply of medicines for the various markets where it operates, namely the US, was the objective of the €30 million investment inaugurated on Friday by Bial at its Trofa campus. In a meeting with journalists on the sidelines of the inauguration of a new antibiotic factory and the expansion of the Portuguese pharmaceutical company’s industrial area, chief executive officer (CEO), António Portela, said it was the “first major industrial investment” made at the campus, which now covers more than 24 hectares and where the company has been based for 27 years.